Clinical trials: Fibrosis
Idiopathic Pulmonary Fibrosis
Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis
Pilot-scale, open-label, fixed-order, two-period crossover study in idiopathic pulmonary fibrosis (IPF) over 16 weeks. Patients will use an electronic health journal (patientMpower platform) to record treatment compliance, forced…
- Trial name
- NCT03104322
- Testing
- patientMpower platform, usual care
- Where
- Ireland
- Volunteers
- 7 people
- Sponsor
- patientMpower Ltd.
Hypertrophic Scar
Hypertrophic Scar Prevention by Novel Topical Gel Application
Researchers are trying to find out more about the side effects of topical (applied to the skin) Pentamidine, to determine if it is safe for use in people.
- Trial name
- NCT03403621
- Testing
- Pentamidine Isethionate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Biliary Atresia
Pentoxifylline Therapy in Biliary Atresia
The purpose of this study is to determine whether pentoxifylline reduces liver damage in infants with biliary atresia.
- Trial name
- NCT01774487
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Baylor College of Medicine
Liver Fibrosis, Hepatic Fibrosis
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
This is a double-blind, multicenter study involving patients with chronic HCV infection who had a liver transplantation; developed HCV-related liver fibrosis and/or incomplete cirrhosis; achieved a sustained virologic response…
- Conditions
- Liver Fibrosis, Hepatic Fibrosis, Liver Cirrhosis, Hepatic Cirrhosis
- Trial name
- POLT-HCV-SVR (NCT02138253)
- Testing
- IDN-6556
- Where
- 35 sites in United States
- Volunteers
- 64 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Cystic Fibrosis
Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations
Based on previous clinical findings, the investigator hypothesize that ivacaftor will have synergistic effects with drugs that facilitate truncated but partially active W1282X CFTR protein processing (tezacaftor) in patients with…
- Trial name
- NCT03624101
- Testing
- Symdeko, Ivacaftor and Symdeko
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Scar, Skin Scarring
Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment
Patients will be randomized either to receive standard daily dressing or hydrocolloid dressing using a randomization generator. After closing the wound with the sutures,the scar will be covered by a hydrocolloid dressing, which…
- Conditions
- Scar, Skin Scarring, Skin Cancer, Wound Heal
- Trial name
- NCT05618912
- Testing
- Hydrocolloid dressing, Petrolatum jelly dressing
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Indiana University
Cystic Fibrosis, Bronchiectasis
Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements
The impact of high-frequency chest wall oscillation therapy on spirometry values (Forced Expiratory Volume, Forced Vital Capacity, Peak Expiratory Flow, Forced Expiratory Flow and Tidal Volume is investigated during use of…
- Trial name
- NCT03534986
- Testing
- International Biophysics AffloVest, Hill-Rom The Vest, Respirtech inCourage
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- International Biophysics Corporation
Reduction in Severity of Skin Scarring
Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001
The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.
- Trial name
- NCT01494922
- Testing
- EXC 001 (currently called PF-06473871)
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Pfizer
Non-alcoholic Steatohepatitis (NASH)
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and…
- Trial name
- NCT04771273
- Testing
- Survodutide
- Where
- 154 sites in United States, Australia and 23 more
- Volunteers
- 295 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function
This study is a multiple within participant crossover study to evaluate the effect of ivacaftor on lung function in participants aged 12 years and older with cystic fibrosis (CF) who have phenotypic or molecular evidence of…
- Trial name
- NCT01685801
- Testing
- Ivacaftor
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cirrhosis of the Liver
HRQoL in the Low MELD Pre-tx Population
The purpose of this study is to describe the HRQoL in those with MELD scores </= 15 in a single center for those who are pre-liver transplant candidates
- Trial name
- LowMELD (NCT01573325)
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Cystic Fibrosis
Blood Flow and Vascular Function in Cystic Fibrosis
Cystic fibrosis (CF) has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections.
- Trial name
- CF-FLOW (NCT02057458)
- Testing
- Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Augusta University
Cystic Fibrosis
International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF1 (NCT00112359)
- Testing
- AZLI 75 mg three times a day (TID)
- Where
- 53 sites in United States, Australia and 2 more
- Volunteers
- 166 people
- Sponsor
- Gilead Sciences
Adhesions, Cesarean Section
Seprafilm® Adhesion Barrier and Cesarean Delivery
A multicenter, randomized, controlled, single blinded study to evaluate the effectiveness of Seprafilm® Adhesion Barrier in reducing adhesion formation in cesarean deliveries.
- Conditions
- Adhesions, Cesarean Section, Delivery, Obstetric
- Trial name
- NCT00565643
- Testing
- modified sodium hyaluronic acid and carboxymethylcellulose
- Where
- 3 sites in United States
- Volunteers
- 753 people, healthy volunteers welcome
- Sponsor
- Winthrop University Hospital
Hepatorenal Syndrome
Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline
Pentoxyfylline therapy in addition to the standard of care of albumin, midodrine and octreotide therapy is superior to the standard of care alone in the treatment of Type I hepatorenal syndrome in the first 14 days of…
- Trial name
- NCT02123576
- Testing
- Pentoxyfylline, AMO Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Patrick Northup, MD
Nonalcoholic Steatohepatitis
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult participants with NASH.
- Trial name
- AURORA (NCT03028740)
- Testing
- Cenicriviroc
- Where
- 346 sites in United States, Australia and 26 more
- Volunteers
- 1,778 people
- Sponsor
- Tobira Therapeutics, Inc.
Cystic Fibrosis
A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation
The study will evaluate the impact of smart adherence technology for monitoring on lumacaftor/ivacaftor (LUM/IVA) adherence rates among subjects 16 years of age and older with Cystic Fibrosis (CF) who are homozygous for the…
- Trial name
- NCT02823470
- Testing
- LUM/IVA, activated smart device, de-activated smart device
- Where
- 11 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1
The primary objective of this trial is to assess the efficacy, safety and pharmacokinetics of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler versus placebo in adolescents and adult patients with cystic…
- Trial name
- NCT04059094
- Testing
- BI 1265162
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 52 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
Study of Ataluren (PTC124™) in Cystic Fibrosis
Cystic fibrosis (CF) is a genetic disorder caused by a mutation in the gene that makes the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
- Trial name
- NCT00803205
- Testing
- Ataluren
- Where
- 38 sites in United States, Belgium and 9 more
- Volunteers
- 238 people
- Sponsor
- PTC Therapeutics
Lung Cancer, Pulmonary Complications
Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy
RATIONALE: Captopril is a drug that may be able to decrease side effects caused by radiation therapy, and may improve the quality of life of patients with non-small cell lung cancer or limited-stage small cell lung cancer.
- Conditions
- Lung Cancer, Pulmonary Complications, Radiation Fibrosis
- Trial name
- NCT00077064
- Testing
- captopril
- Where
- 87 sites in United States
- Volunteers
- 81 people
- Sponsor
- Radiation Therapy Oncology Group